Myasthenia gravis is an autoimmune disorder in which antibodies disrupt the communication between nerves and muscles, ...

SU11657 (SUGEN) is a selective multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity exerted by targeting PDGF receptors ... All antibodies were diluted in 0.1% ...

Comparison of Commission on Cancer–Approved and –Nonapproved Hospitals in the United States: Implications for Studies That Use the National Cancer Data Base We performed a phase I, pharmacologic, and ...

The epidermal growth factor receptor (EGFR), a long-standing drug development ... to identify lead molecules for labeling and in vivo evaluation. A new EGFR tyrosine kinase radiometric binding assay ...

Collaborative Innovation Centre of Henan Province for Green Manufacturing of Fine Chemicals, Key Laboratory of Green Chemical Media and Reactions, Ministry of Education, Henan Engineering Research ...

CSF1R is a tyrosine kinase receptor expressed on macrophages, including EIMs. The proliferation, differentiation, and survival of many tissue-resident macrophages rely on signaling through the ...

1Research Institute Children’s Cancer Center Hamburg, Hamburg, Germany. 2Department of Pediatric Hematology and Oncology, University Medical Center Hamburg, Hamburg, Germany.

bCenter for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN, USA cDepartment of Pediatrics and the Herman B Wells Center for Pediatric Research, Indiana ...

The research she presented focused on neovascular age-related macular degeneration (AMD). "This is actually the first phase 2 study looking at a tyrosine kinase inhibitor for wet AMD," Dr. Talcott ...

FMS-like tyrosine kinase 3 (FLT3 ... (PE)-conjugated and annexin V-PE antibodies were from BD Pharmingen (San Jose, CA, USA). PhosphoMAP kinase, phosphoSTAT5, phosphoAKT, MAP kinase and AKT ...

"This approach works for multiple antibodies targeting different immune receptors. The ability to engineer these rigid antibodies could help develop more potent drugs that can stimulate the immune ...

Germline Genetic Testing for Women With Breast Cancer: Shifting the Paradigm From Whom to Test to Whom NOT to Test In the article accompanying this editorial, ELEVATE RR study is a phase III, ...